- In October 2023, Sumitomo Pharma Canada, Inc., an innovative healthcare company, and Pfizer Canada, a pharmaceutical firm, announced that Health Canada issued a Notice of Compliance (NOC) for MYFEMBREE (relugolix, estradiol, and norethindrone acetate tablets). This medication is approved for treating moderate to severe endometriosis pain in premenopausal women. Earlier, on September 22, 2023, Health Canada also authorized MYFEMBREE for managing heavy menstrual bleeding caused by uterine fibroids in premenopausal women. This oral combination therapy is taken once daily and offers women a new treatment option for alleviating symptoms of endometriosis and uterine fibroids
- In June 2022, ObsEva SA, a biopharmaceutical company, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved Yselty (linzagolix), an oral GnRH antagonist, for the treatment of moderate to severe uterine fibroids in adult women of reproductive age (18 years and older)
- In August 2022, MYFEMBREE, a product developed in partnership by Pfizer, Inc. and Myovant Sciences, received approval from the U.S. FDA for managing moderate to severe pain related to both menstrual and non-menstrual conditions. This regulatory approval allowed the product to enter the market, enhancing their product offerings
- In May 2021, Myovant Sciences, in collaboration with Pfizer Inc., announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). This marks the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration of up to 24 months
- In May 2020, AbbVie, a pharmaceutical company, and Neurocrine Biosciences, Inc., a biopharmaceutical firm, revealed that the U.S. FDA approved ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules). ORIAHNN is the first non-surgical, oral medication authorized by the U.S. FDA for managing heavy monthly bleeding due to uterine fibroids in premenopausal women
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids, and Pedunculated Fibroids), Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs, and Vitamins), Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene, and Others), Diagnosis (Ultrasound, Lab Tests, and Imaging Tests), Treatment (Medication, Dietary Supplements, and Surgery), Route of Administration (Oral, Intravenous, and Others), End-User (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032
.
The Global Uterine Fibroids Drug Market size was valued at USD 1.64 USD Billion in 2024.
The Global Uterine Fibroids Drug Market is projected to grow at a CAGR of 9.2% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
